ArticleClinical and translational radiation oncology2026
Pharyngeal mucositis and esophagitis after re-irradiation spine stereotactic body radiotherapy with 24 Gy in two fractions.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pharyngeal mucositis and esophagitis incidence following re-irradiation stereotactic body radiotherapy (SBRT) for spinal metastases remains unclear. We retrospectively examined their incidence and risk factors after re-irradiation SBRT to clarify organ tolerance. Methods and materials: Patients who underwent spine SBRT following prior conventional radiotherapy were included if the SBRT delivered more than 10 Gy to the pharynx or esophagus. SBRT dose was limited to 24 Gy in two fractions. Dose constraints were pharyngeal D Results: Ninety-three patients were included (60 males; median age, 66 years). The median follow-up was 15 (range: 3-111) months. One patient with grade 3 toxicity (1 %) was observed, with no grade 4-5 toxicities. Grade 1 (symptomatic) pharyngeal mucositis occurred in 58 % (14/24) of patients, and grade 2 esophagitis occurred in 27 % (23/85). Clinical factors and symptomatic toxicities were not significantly associated. The estimated D Conclusions: Grade ≥ 3 pharyngeal mucositis and esophagitis were rare; the current dose constraints are safe for re-irradiated spine SBRT. Reducing the pharyngeal and esophageal maximum doses may be helpful among patients for whom avoiding symptomatic mucositis is particularly important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.